Surgical Complications After Neoadjuvant Treatment for Borderline Resectable Pancreatic Cancer: From Benchmarks to Randomized Clinical Trials
Open Access
- 31 August 2024
- journal article
- editorial
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 31 (13) , 8481-8484
Abstract
No abstract availableThis publication has 15 references indexed in Scilit:
- Neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer (NORPACT-1): a multicentre, randomised, phase 2 trialThe Lancet Gastroenterology & Hepatology, 2024
- Pancreatic surgery outcomes: multicentre prospective snapshot study in 67 countriesBritish Journal of Surgery, 2023
- Consensus recommendations on how to assess the quality of surgical interventionsNature Medicine, 2023
- Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trialThe Lancet Gastroenterology & Hepatology, 2022
- Efficacy of Preoperative mFOLFIRINOX vs mFOLFIRINOX Plus Hypofractionated Radiotherapy for Borderline Resectable Adenocarcinoma of the PancreasJAMA Oncology, 2022
- Consensus Statement on Mandatory Measurements for Pancreatic Cancer Trials for Patients With Resectable or Borderline Resectable Disease (COMM-PACT-RB)JAMA Oncology, 2022
- Neoadjuvant therapy or upfront surgery for resectable and borderline resectable pancreatic cancer: A meta-analysis of randomised controlled trialsEuropean Journal of Cancer, 2022
- The effect of preoperative chemotherapy and chemoradiotherapy on pancreatic fistula and other surgical complications after pancreatic resection: a systematic review and meta-analysis of comparative studiesHPB, 2021
- Neoadjuvant Therapy for Pancreatic CancerAmerican Journal of Clinical Oncology, 2016
- Subgroup analyses in randomized trials: risks of subgroup-specific analyses;Journal of Clinical Epidemiology, 2004